ARTICLE | Finance
Ebb & Flow
January 12, 2009 8:00 AM UTC
As one of the few remaining independent vaccine businesses, Crucell (Euronext:CRXL; NASDAQ:CRXL) has been touted as a potential acquisition candidate. Late last Wednesday, the Dutch vaccines company essentially flagged up to the marketplace that it is willing to be taken out when it revealed that Wyeth (NYSE:WYE) had started preliminary "friendly discussions" that could lead to a takeover.
The news prompted an immediate gain of $4.43 (28%) to $20.50 on NASDAQ on Wednesday. On Thursday, Crucell advanced €4.92 (42%) to €16.50. Crucell closed the week up €5.635 (49%) at €17.10, while its ADSs gained $7.39 to $23.29...